Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease
Beam expects to submit risto-cel for U.S. approval as early as year-end 2026 following the trial’s endpoint results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) announced that its BEACON Phase 1/2 trial of risto-cel in sickle cell disease met its primary efficacy endpoint.
The endpoint was freedom from severe vaso-occlusive crises, or blood-flow-blocking episodes, for at least 12 consecutive months, based on independently adjudicated results. The prespecified interim analysis met all primary safety and secondary efficacy endpoints, including freedom from inpatient hospitalization for severe crises for at least 12 consecutive months. At the October 20, 2026 cutoff, 39 adults and 10 adolescents had received treatment; 31 patients had completed required efficacy follow-up. Safety findings were consistent with earlier data and known treatment-process effects and underlying disease. Beam expects a U.S. approval application as early as year-end 2026 and plans detailed pivotal results at a medical meeting in 2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointPrimary efficacy endpoint met: freedom from severe crises for at least 12 consecutive months, independently adjudicated.
- Moderate point. Forward-looking: it has not happened yet and may not happen.U.S. approval application for risto-cel expected as early as year-end 2026.
- Minor pointAll primary safety endpoints met; findings remained consistent with earlier data, known treatment-process effects and underlying disease.
- Minor pointAll secondary efficacy endpoints met, including freedom from severe-crisis inpatient hospitalization for at least 12 consecutive months.
Negative
- Minor pointPrespecified interim analysis: 31 patients completed required efficacy follow-up; 39 adults and 10 adolescents had been treated.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEACON Trial Achieved Primary Efficacy Endpoint of Freedom from Severe Vaso-occlusive Crises (VOCs) for at Least 12 Consecutive Months, Based on Independently Adjudicated Results, and Met All Primary Safety Endpoints at the Prespecified Interim Analysis
Study Met All Secondary Endpoints Including Freedom from Inpatient Hospitalization for Severe VOCs for 12 Consecutive Months
Results Support Planned U.S. Biologics License Application (BLA) Submission for risto-cel, Expected as Early as Year-End 2026
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced positive topline results from the BEACON Phase 1/2 study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs). Risto-cel is an investigational one-time, autologous cell therapy with a potentially differentiated profile for the treatment of SCD.
BEACON achieved the primary efficacy endpoint of freedom from severe VOCs for at least 12 consecutive months (VF12) based on independently adjudicated results and met all primary safety endpoints at the prespecified interim analysis. As of the October 20, 2026, data cutoff, a total of 39 adults and 10 adolescents were treated in the BEACON trial, and 31 patients had completed the required follow-up period for the VF12 endpoint. The study also met all secondary efficacy endpoints, including freedom from inpatient hospitalization for severe VOCs for at least 12 consecutive months. The safety findings observed as of the data cutoff date were consistent with previously reported data from the BEACON study and with the known and intended effects of plerixafor use and the cell collection process, myeloablative conditioning with busulfan, the autologous hematopoietic stem cell transplantation (HSCT) process, and underlying SCD.
“These positive topline results represent a defining milestone for risto-cel and for Beam’s base editing technology more broadly, bringing us an important step closer to delivering a potentially transformative, one-time treatment for people living with sickle cell disease,” said John Evans, chief executive officer of Beam Therapeutics. “For patients with SCD, severe vaso-occlusive crises can be debilitating and life-threatening, making sustained freedom from these events an important clinical outcome. The achievement of our primary efficacy endpoint, supported by the broader clinical safety and efficacy profile observed in the BEACON trial, reinforces our confidence in risto-cel. With these results in hand, we are focused on submitting our planned BLA as early as year-end, which has the potential to be the first BLA for a base editing therapy.”
Beam expects to submit a Biologics License Application (BLA) for risto-cel to the U.S. Food and Drug Administration (FDA) as early as the end of 2026. Detailed pivotal results from the BEACON study are planned for presentation at a medical meeting in 2027.
Separately, Beam will present results from an earlier data cutoff from the BEACON clinical trial of risto-cel in SCD in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans.
About ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101)
Risto-cel is an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). The one-time therapy consists of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that have been base-edited in the promoter regions of the HBG1/2 genes and are administered via a hematopoietic stem cell transplant procedure. The risto-cel edit is designed to inhibit the transcriptional repressor BCL11A from binding to the promoter without disrupting BCL11A expression, which is intended to lead to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimic the effects of naturally occurring variants seen in hereditary persistence of fetal hemoglobin. HbF is the predominant hemoglobin variant during development and early life. The safety and efficacy of risto-cel are being evaluated in the ongoing BEACON Phase 1/2 study, an open-label, single-arm, multicenter trial in patients with SCD with severe vaso-occlusive crises (VOCs).
About Sickle Cell Disease
Sickle cell disease (SCD), a severe inherited blood disease, is caused by a single point mutation, E6V, in the beta globin gene. This mutation causes the mutated form of sickle hemoglobin (HbS) to aggregate into long, rigid molecules that bend red blood cells into a sickle shape under conditions of low oxygen. Sickled cells obstruct blood vessels and die prematurely, ultimately resulting in anemia, severe pain (crises), infections, stroke, organ failure and early death. SCD is the most common inherited blood disorder in the United States (U.S.), affecting an estimated 100,000 individuals within the U.S. and approximately eight million people worldwide.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic potential and anticipated clinical benefits of risto-cel, including the expected one-time nature of the therapy; our plans, and anticipated timing, to advance our risto-cel program, including the anticipated timing of our BLA submission to the FDA; the potential for our BLA submission for risto-cel to be the first BLA for a base editing therapy; the potential for the results from the BEACON trial to support a BLA submission for risto-cel; the potential acceptance, review and approval of any such BLA by the FDA; the potential commercialization of risto-cel, if approved; our plans for presentation of additional results from the BEACON trial; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: whether topline results, including results from a prespecified interim analysis, will be consistent with final or more detailed results; whether the BEACON results will be sufficient to support submission or approval of a BLA; whether the FDA will accept any BLA for filing or require additional clinical, preclinical, manufacturing or other data; whether risto-cel will receive regulatory approval on the timeline anticipated or at all; the potential for new safety findings or other information to emerge as additional patients are treated or followed for longer periods, including the risk that treatment effects may not prove durable over longer follow-up periods; our ability to develop, obtain regulatory approval for, and commercialize our product candidates, including risto-cel, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty regarding our ability to obtain or maintain regulatory authorizations necessary to initiate or continue human clinical trials for our product candidates; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products, including gene therapies already approved for SCD; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Contacts:
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Media:
Josie Butler
1AB
josie@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.